A citation-based method for searching scientific literature

Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, Kris Jardon, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley F Haggerty, Maria J Rubio-Pérez, Mark S Shahin, Giorgia Mangili, William H Bradley, Ilan Bruchim, Kaiming Sun, Izabela A Malinowska, Yong Li, Divya Gupta, Bradley J Monk. N Engl J Med 2019
Times Cited: 338

Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh, Anke Reinacher-Schick, Giampaolo Tortora, Hana Algül, Eileen M O'Reilly, David McGuinness, Karen Y Cui, Katia Schlienger, Gershon Y Locker, Hedy L Kindler. N Engl J Med 2019
Times Cited: 487

List of shared articles

Times cited

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Pierre-Marie Morice, Alexandra Leary, Charles Dolladille, Basile Chrétien, Laurent Poulain, Antonio González-Martín, Kathleen Moore, Eileen Mary O'Reilly, Isabelle Ray-Coquard, Joachim Alexandre. Lancet Haematol 2021

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Talia Golan, Grainne M O'Kane, Robert E Denroche, Maria Raitses-Gurevich, Robert C Grant, Spring Holter, Yifan Wang, Amy Zhang, Gun Ho Jang, Chani Stossel,[...]. Gastroenterology 2021

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.
R Danesi, S Fogli, S Indraccolo, M Del Re, A P Dei Tos, L Leoncini, L Antonuzzo, L Bonanno, V Guarneri, A Pierini,[...]. ESMO Open 2021

Clinical considerations for the management of androgen indifferent prostate cancer.
Jacob E Berchuck, Paul V Viscuse, Himisha Beltran, Ana Aparicio. Prostate Cancer Prostatic Dis 2021

Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Fengping Shao, Yaoyun Duan, Yunhe Zhao, Yinguang Li, Jun Liu, Cai Zhang, Shanyang He. Aging (Albany NY) 2021

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
Roni Nitecki, Alexander Melamed, Allison A Gockley, Jessica Floyd, Kate J Krause, Robert L Coleman, Ursula A Matulonis, Sharon H Giordano, Karen H Lu, J Alejandro Rauh-Hain. Gynecol Oncol 2021

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R Grimes, Robert L Hollis, C Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson,[...]. Clin Cancer Res 2021

Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
Pierre-Marie Morice, Elodie Coquan, Louis-Bastien Weiswald, Bernard Lambert, Dominique Vaur, Laurent Poulain. Br J Cancer 2021

The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Michelle Shen, Shiqin Liu, Tanya Stoyanova. Am J Clin Exp Urol 2021

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido,[...]. Eur J Cancer 2021